Skip to main content

Table 1 Baseline Clinical Characteristics

From: Dose-response association of implantable device-measured physical activity with long-term cardiac death and all-cause mortality in patients at high risk of sudden cardiac death: a cohort study

  Total (n = 822) Tertile 1 (n = 274) Tertile 2 (n = 274) Tertile 3 (n = 274) P value
Demographics
 Male 607 (73.8) 187 (68.3) 206 (75.2) 214 (78.1) 0.026
 Physical activity, % 11.0 ± 5.8 4.9 ± 2.0 10.6 ± 1.5 17.5 ± 3.9 < 0.001
 Age at implantation, years 60.8 ± 13.8 65.5 ± 13.2 61.1 ± 13.4 55.7 ± 13.1 < 0.001
 BMI, kg/m2 23.6 ± 3.4 23.5 ± 3.7 23.5 ± 3.5 23.8 ± 3.4 0.293
 Primary prevention 434 (52.8) 146 (53.3) 146 (53.3) 142 (51.8) 0.925
 NYHA, class I–II 420 (51.1) 106 (38.7) 143 (52.2) 171 (62.4) < 0.001
 CRTD 217 (26.4) 82 (29.9) 76 (27.7) 59 (21.5) 0.069
Comorbidities
 Ischemic cardiomyopathy 281 (34.2) 115 (42.0) 103 (37.6) 63 (23.0) < 0.001
 Hypertension 259 (31.5) 92 (33.6) 96 (35.0) 71 (25.9) 0.047
 Diabetes 78 (9.5) 39 (14.2) 20 (7.3) 19 (6.9) 0.005
 Stroke 16 (1.9) 10 (3.7) 3 (1.1) 3 (1.1) 0.044
 Atrial fibrillation 90 (10.9) 33 (12.0) 31 (11.3) 26 (9.5) 0.615
 Valvular disease 20 (2.4) 9 (3.28) 8 (2.92) 3 (1.09) 0.204
 Prior myocardial infarction 128 (15.6) 60 (21.9) 45 (16.4) 23 (8.4) < 0.001
 Pre-implant syncope 175 (21.3) 57 (20.8) 52 (19.0) 66 (24.1) 0.334
Echocardiography
 LVEF, % 42.7 ± 14.9 40.2 ± 14.6 42.9 ± 14.5 44.9 ± 15.3 < 0.001
 LVEDD, mm 58.6 ± 13.1 58.9 ± 12.0 58.7 ± 13.6 58.1 ± 13.6 0.586
Medication
 Beta-blockers 507 (61.7) 169 (61.7) 167 (61.0) 171 (62.4) 0.940
 ACEIs/ARBs 321 (39.1) 116 (42.3) 106 (38.7) 99 (36.1) 0.327
 Aldosterone antagonists 295 (35.9) 14 (45.3) 96 (35.0) 75 (27.4) < 0.001
 Statins 192 (23.4) 71 (25.9) 65 (23.7) 56 (2.4) 0.313
 Loop diuretics 340 (41.4) 134 (48.9) 119 (43.4) 87 (31.8) < 0.001
 Digoxins 170 (20.7) 68 (24.8) 54 (19.7) 48 (17.5) 0.096
 Amiodarone 250 (30.4) 87 (31.8) 84 (30.7) 79 (28.8) 0.755
  1. Abbreviations: ACEIs angiotensin-converting enzyme inhibitors, ARBs angiotensin receptor blockers, BMI Body Mass Index, CRTD cardiac resynchronization therapy and implantable cardioverter-defibrillator, LVEDD left ventricular end-diastolic dimension, LVEF left ventricular ejection fraction, NYHA class New York Heart Association class